Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients.

Mosleh, Ema; Snyder, Stacy; Wu, Ningying; Willis, Daniel N; Malone, Rema; Hayashi, Robert J

Mosleh, Ema; Snyder, Stacy; Wu, Ningying; Willis, Daniel N; Malone, Rema; Hayashi, Robert J.

Afiliação

Mosleh E; Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.
Snyder S; Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.
Wu N; Biostatistics Shared Resource, Division of Public Health Sciences and Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States.
Willis DN; Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.
Malone R; Division of Pediatric Hematology/Oncology, St. Louis Children's Hospital, St. Louis, MO, United States.
Hayashi RJ; Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.

Front Oncol ; 13: 1280587, 2023.

Article em En | MEDLINE | ID: mdl-37965460

Palavras-chave

AYA; HDMTX; adverse effect; delayed clearance; methotrexate; nephrotoxicity; pediatric cancer; supportive care

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google